Expanding the Target Landscape by Drugging the Undruggable (R21 Clinical Trial Not Allowed)

Federal funding opportunity PAR-25-442 from National Institutes of Health (Department of Health and Human Services).

Apply on Grants.gov →Application closes February 17, 2028

Program funding history

Synopsis

Who can apply

• Native American tribal governments (Federally recognized)
• Private institutions of higher education
• Special district governments
• State governments
• Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education
• Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education
• Public housing authorities/Indian housing authorities
• County governments
• Independent school districts
• City or township governments
• For profit organizations other than small businesses
• Others (see text field entitled "Additional Information on Eligibility" for clarification)
• Public and State controlled institutions of higher education
• Native American tribal organizations (other than Federally recognized tribal governments)
• Small businesses

Other Eligible Applicants include the following: Alaska Native and Native Hawaiian Serving Institutions; Asian American Native American Pacific Islander Serving Institutions (AANAPISISs); Eligible Agencies of the Federal Government; Faith-based or Community-based Organizations; Hispanic-serving Institutions; Historically Black Colleges and Universities (HBCUs); Indian/Native American Tribal Governments (Other than Federally Recognized); Regional Organizations; Tribally Controlled Colleges and Universities (TCCUs) ; U.S. Territory or Possession; Non-domestic (non-U.S.) Entities (Foreign Organizations) are not eligible to apply. Non-domestic (non-U.S.) components of U.S. Organizations are not eligible to apply. Foreign components, as defined in the NIH Grants Policy Statement, are not allowed.

How to apply

Similar grants

• Catalyze: Product Definition for Small Molecules, Biologics and Combination Products - Target Identification and Validation, and Preliminary Product/Lead Series Identification (R61/R33 Clinical Trials Not Allowed)
  RFA-HL-26-017 · National Institutes of Health · closes December 23, 2027
• Blueprint MedTech Translator (UG3/UH3 - Clinical Trial Optional)
  PAR-25-383 · National Institutes of Health · closes January 28, 2028
• Stimulating Access to Research in Residency (StARR) (R38 Independent Clinical Trial Not Allowed)
  RFA-HL-26-012 · National Institutes of Health · closes January 10, 2028
• Limited Competition: CCRP Initiative: Promoting a Basic Understanding of Chemical Threats to Skin (R34 Clinical Trial Not Allowed)
  PA-25-093 · National Institutes of Health · closes January 7, 2028
• Dissemination and Implementation Research in Health (R01 Clinical Trial Optional)
  PAR-25-144 · National Institutes of Health · closes January 7, 2028
• Dissemination and Implementation Research in Health (R03 Clinical Trial Not Allowed)
  PAR-25-233 · National Institutes of Health · closes January 7, 2028